Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
Conversion Labs (NASDAQ: CVLB), a leading telehealth company, will present at the BTIG Virtual MedTech Conference from February 17-19, 2021. CEO Justin Schreiber and CBO Corey Deutsch will lead a fireside chat on February 18 at 1:00 PM ET. The event will include virtual meetings with institutional investors. The company recently announced plans to rebrand as LifeMD on February 22, introducing subscription-based primary care services. 2020 saw a 205% revenue increase to $38 million, with a projected annual recurring revenue of $26 million.
- None.
- None.
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held on February 17-19, 2021.
Conversion Labs CEO Justin Schreiber is scheduled to present in a fireside chat on Thursday, February 18 at 1:00 p.m. Eastern time. He will be joined by the company’s chief business officer, Corey Deutsch, for the presentation and virtual one-on-one meetings with institutional analysts and investors throughout the conference.
The presentation will be webcast live and available for replay here and via the investor relations section of the company’s website at ConversionLabs.com.
Management will discuss the company’s recently announced plans to change its name to LifeMD on February 22. The name change will be followed by the official launch of its subscription-based primary care and concierge services designed to positively transform all aspects of a patient’s healthcare. LifeMD’s mobile-first interface will be powered by the company’s proprietary Veritas MD digital health platform, providing a seamless integration between doctors, patients, medical information and pharmacy.
Management will also discuss the company’s recently reported preliminary results for 2020, with revenue up
Register for the conference here. To schedule a one-on-one meeting with the company, please contact your BTIG representative. To learn more about Conversion Labs, contact Ron Both of CMA at (949) 432-7557 or submit your request here.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. To learn more about BTIG, visit www.btig.com.
About Conversion Labs
Conversion Labs, Inc. is a leading telehealth company offering a full portfolio of direct-to-patient products and services. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
LifeMD™, Veritas MD™, Shapiro MD™, Rex MD™ and Nava MD™ are trademarks of Conversion Labs. All other trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
FAQ
When is Conversion Labs' presentation at the BTIG Conference?
What was Conversion Labs' revenue growth in 2020?
What is the significance of the name change for CVLB?
What are the subscription services being launched by Conversion Labs?
How does the digital health platform support Conversion Labs?
